Rituximab used in three cases with relapsed non-Hodgkin's lymphoma

Creative Commons License

Elli M., Yilmaz S., Aydin R., Murat S., Ceyhan Bilgici M. N., Dağdemir A.

MOLECULAR AND CLINICAL ONCOLOGY, cilt.1, sa.3, ss.550-552, 2013 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3892/mco.2013.88
  • Dergi Adı: MOLECULAR AND CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.550-552
  • Anahtar Kelimeler: rituximab, non-Hodgkin's lymphoma, relapse, children
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti-CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab.